ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Vietnam homegrown COVID vaccine heads for full approval by year-end

Doses enter Phase 3 trials, but Hanoi could approve emergency use as cases climb

A Vietnamese health care worker administers the Nanocovax vaccine candidate, which has entered the final phase of clinical trials. (Photo by Vietnam News Agency)

HANOI -- Vietnam's domestically developed coronavirus vaccine candidate has begun Phase 3 clinical trials, with the country hoping to package doses for market by the end of the year.

Nanocovax, developed by startup Nanogen Pharmaceutical Biotechnology in collaboration with Vietnam Military Medical University, started the final trials on Thursday, the company said. About 13,000 people will participate in the trials, and the results will be compiled by September, Nanogen said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more